Skip to main content
EJNMMI Research
Fig. 6 | EJNMMI Research

Fig. 6

From: Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007

Fig. 6

PET/MR imaging in a mCRPC patient (PSA 392 ng/ml) using EuE-k-18F-FBOA (1) demonstrates intensive PSMA-ligand uptake in multiple bone (arrows) and tiny subcentimeter lymph node (dotted arrows) metastases. Maximum intensity projection (a) shows distribution of disease. Sets b and c shows coronal and axial MR (T1 and T2 haste), PET and fused images with arrows and dotted arrows representing bone and lymph node metastases, respectively

Back to article page